Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 20, 2016 08:30 ET | Source: Minerva Neurosciences, Inc.

Minerva Neurosciences Names Michael Davidson, M.D. as Chief Medical Officer

WALTHAM, Mass., Dec. 20, 2016 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
December 05, 2016 08:00 ET | Source: Minerva Neurosciences, Inc.

Minerva Neurosciences’ Clinical Data Featured at The American College of Neuropsychopharmacology Annual Meeting

Oral presentation highlights specific improvements in negative symptoms and cognition observed in schizophrenic patients treated with MIN-101 in Phase IIB trial Data also presented from Phase IIA...
November 10, 2016 08:30 ET | Source: Minerva Neurosciences, Inc.

Minerva Neurosciences to Present at Jefferies 2016 London Healthcare Conference on November 17, 2016

WALTHAM, Mass., Nov. 10, 2016 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
November 03, 2016 07:30 ET | Source: Minerva Neurosciences, Inc.

Minerva Neurosciences Reports Third Quarter 2016 Financial Results and Business Updates

WALTHAM, Mass., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
October 27, 2016 08:30 ET | Source: Minerva Neurosciences, Inc.

Minerva Neurosciences to Report Third Quarter 2016 Financial Results and Business Updates on November 3, 2016

WALTHAM, Mass., Oct. 27, 2016 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
October 26, 2016 08:30 ET | Source: Minerva Neurosciences, Inc.

Minerva Neurosciences Announces Positive Data From Six-Month Extension of Phase IIb Trial of MIN-101 Monotherapy in Schizophrenia

WALTHAM, Mass., Oct. 26, 2016 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
October 13, 2016 08:30 ET | Source: Minerva Neurosciences, Inc.

Minerva Neurosciences Announces Acceptance of Presentations of Clinical Data With MIN-101 and MIN-117 at American College of Neuropsychopharmacology Annual Meeting

WALTHAM, Mass., Oct. 13, 2016 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
September 26, 2016 08:30 ET | Source: Minerva Neurosciences, Inc.

Minerva Neurosciences Provides Update on MIN-101 and MIN-117 Clinical Programs

Last patient completes extension phase of Phase IIb trial with MIN-101 Company receives FDA acceptance of Investigational New Drug Application for MIN-117 WALTHAM, Mass., Sept. 26, 2016 (GLOBE...
September 02, 2016 08:30 ET | Source: Minerva Neurosciences, Inc.

Minerva Neurosciences to Present at 23rd Annual NewsMakers in the Biotech Industry Conference on September 9, 2016

WALTHAM, Mass., Sept. 02, 2016 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat...
August 04, 2016 07:30 ET | Source: Minerva Neurosciences, Inc.

Minerva Neurosciences Reports Second Quarter 2016 Financial Results and Business Updates

Positive clinical data advance development with MIN-101 in schizophrenia and MIN-117 in major depressive disorder Additional trials also planned with MIN-202 in insomnia disorder and major...